Zilebesiran

DB18929InvestigationalGene Therapies

Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)).

Mechanism: Pharmacologically active on Angiotensinogen
Curator reviewed
Also known as: (2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17- triazanonacosan-29-oyl}-4-hydroxypyrrolidin-
Code names: AD-85481 · ALN-85481 · ALN-AGT01

Resolves to

Compound

UNIIE422BH4BRKCAS2380166-33-4

Targets

P01019AGT

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zilebesiran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account